The Effect of Thiazolidinediones in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
FBG
FI
Glitazones
HOMA-B
HOMA-IR
Metformin
PCOS
Pharmacological therapy
Pioglitazone
Polycystic ovary syndrome
Rosiglitazone
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
29 Apr 2024
29 Apr 2024
Historique:
received:
16
01
2024
accepted:
18
03
2024
medline:
29
4
2024
pubmed:
29
4
2024
entrez:
29
4
2024
Statut:
aheadofprint
Résumé
Polycystic ovary syndrome (PCOS) is a complex endocrine condition affecting women of reproductive age. It is characterised by insulin resistance and is a risk for type 2 diabetes mellitus (T2DM). The aim of this study was to review the literature on the effect of pioglitazone and rosiglitazone in women with PCOS. We searched PubMed, MEDLINE, Scopus, Embase, Cochrane Library and the Web of Science in April 2020 and updated in March 2023. Studies were deemed eligible if they were randomised controlled trials (RCTs) reporting the effect of pioglitazone and rosiglitazone in PCOS. The study follows the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Two reviewers independently extracted data and assessed the risk of bias using the Cochrane risk of bias tool. Out of 814 initially retrieved citations, 24 randomised clinical trials (RCTs) involving 976 participants were deemed eligible. Among women with PCOS, treatment with rosiglitazone compared to metformin resulted in a significant increase in the mean body weight (mean difference (MD) 1.95 kg; 95% CI 0.03-3.87, p = 0.05). Metformin treatment was associated with a reduction in mean body mass index (BMI) compared to pioglitazone (MD 0.85 kg/m Both pioglitazone and rosiglitazone were associated with significant increases in body weight and BMI when compared with metformin or placebo. Pioglitazone significantly reduced triglycerides and fasting insulin when compared with placebo while rosiglitazone showed a modest reduction of LH when compared with metformin. CRD42020178783.
Identifiants
pubmed: 38683294
doi: 10.1007/s12325-024-02848-3
pii: 10.1007/s12325-024-02848-3
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature.
Références
Barnard L, Ferriday D, Guenther N, Strauss B, Balen AH, Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod. 2007;22(8):2279–86.
pubmed: 17537782
doi: 10.1093/humrep/dem108
Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence. Ther Adv Endocrinol Metab. 2021;12:2042018821989238.
pubmed: 33552465
pmcid: 7844452
doi: 10.1177/2042018821989238
Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. P T. 2013;38(6):336–55.
pubmed: 23946629
pmcid: 3737989
Witchel SF, Oberfield SE, Pena AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019;3(8):1545–73.
pubmed: 31384717
pmcid: 6676075
doi: 10.1210/js.2019-00078
Abdalla M, Deshmukh H, Atkin SL, Sathyapalan T. miRNAs as a novel clinical biomarker and therapeutic targets in polycystic ovary syndrome (PCOS): a review. Life Sci. 2020;259: 118174.
pubmed: 32745529
doi: 10.1016/j.lfs.2020.118174
Wu S, Divall S, Wondisford F, Wolfe A. Reproductive tissues maintain insulin sensitivity in diet-induced obesity. Diabetes. 2012;61(1):114–23.
pubmed: 22076926
doi: 10.2337/db11-0956
Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O’Keefe M, Ghazzi MN. Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003;79(4):932–7.
pubmed: 12749433
doi: 10.1016/S0015-0282(02)04914-2
Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92(12):4546–56.
pubmed: 18056778
doi: 10.1210/jc.2007-1549
Garruti G, Depalo R, Vita MG, et al. Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. Reprod Biomed Online. 2009;19(4):552–63.
pubmed: 19909598
doi: 10.1016/j.rbmo.2009.05.010
Essah PA, Wickham EP, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol. 2007;50(1):205–25.
pubmed: 17304037
doi: 10.1097/GRF.0b013e31802f3547
Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111–20.
pubmed: 16291981
doi: 10.1056/NEJMoa050156
Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020;11:2042018820938305.
pubmed: 32670541
pmcid: 7338645
doi: 10.1177/2042018820938305
Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 2002;18(Suppl 2):S10-15.
pubmed: 11921433
doi: 10.1002/dmrr.249
Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med. 2007;356(24):2522–4.
pubmed: 17517854
doi: 10.1056/NEJMe078099
Ajjan RA, Grant PJ. The cardiovascular safety of rosiglitazone. Expert Opin Drug Saf. 2008;7(4):367–76.
pubmed: 18613801
doi: 10.1517/14740338.7.4.367
Bailey CJ. Thiazolidinediones. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. Elsevier; 2007. https://doi.org/10.1016/B978-008055232-3.61047-5 .
Valsamakis G, Lois K, Kumar S, Mastorakos G. Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS). Hormones (Athens). 2013;12(3):363–78.
pubmed: 24121378
doi: 10.1007/BF03401302
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
pubmed: 33782057
pmcid: 8005924
doi: 10.1136/bmj.n71
Babineau J. Product review: Covidence (systematic review software). J Can Health Libr Assoc. 2014;35(2):68–71.
doi: 10.5596/c14-016
Das S, Chatterjee SS. Cabell’s blacklist: a new way to tackle predatory journals. Indian J Psychol Med. 2018;40(2):197–8.
pubmed: 29962584
pmcid: 6008990
doi: 10.4103/IJPSYM.IJPSYM_290_17
Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.
pubmed: 22008217
pmcid: 3196245
doi: 10.1136/bmj.d5928
Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Wiley; 2019.
doi: 10.1002/9781119536604
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
pubmed: 18436948
pmcid: 2335261
doi: 10.1136/bmj.39489.470347.AD
Shahebrahimi K, Jalilian N, Bazgir N, Rezaei M. Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome. Indian J Endocrinol Metab. 2016;20(6):805–9.
pubmed: 27867884
pmcid: 5105565
doi: 10.4103/2230-8210.192925
Sohrevardi SM, Nosouhi F, Hossein Khalilzade S, et al. Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: an RCT. Int J Reprod Biomed. 2016;14(12):743–54.
pubmed: 28331909
pmcid: 5203689
Cetinkalp S, Karadeniz M, Erdogan M, Ozgen G, Saygl F, Ylmaz C. The effects of rosiglitazone, metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary syndrome. Endocrinologist. 2009;19(3):94–7.
doi: 10.1097/TEN.0b013e3181a58772
Kilicdag EB, Bagis T, Zeyneloglu HB, et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod. 2005;20(4):894–9.
pubmed: 15618250
doi: 10.1093/humrep/deh700
Lam PM, Tam WH, Ma RC, et al. The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome—a double-blind randomized placebo-controlled study. Fertil Steril. 2011;96(2):445–451.e441.
pubmed: 21722894
doi: 10.1016/j.fertnstert.2011.05.085
Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol. 2009;70(2):233–7.
doi: 10.1111/j.1365-2265.2008.03309.x
Li Y, Tan J, Wang Q, Duan C, Hu Y, Huang W. Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. 2020;113(1):197–204.
pubmed: 31718828
doi: 10.1016/j.fertnstert.2019.09.011
Ziaee A, Oveisi S, Abedini A, Hashemipour S, Karimzadeh T, Ghorbani A. Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. Acta Med Indones. 2012;44(1):16–22.
pubmed: 22451180
Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(8):3835–40.
pubmed: 15292314
doi: 10.1210/jc.2003-031737
Mohiyiddeen L, Watson AJ, Apostolopoulos NV, Berry R, Alexandraki KI, Jude EB. Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome. J Obstet Gynaecol. 2013;33(2):165–70.
pubmed: 23445141
doi: 10.3109/01443615.2012.745839
Yilmaz M, Karakoç A, Törüner FB, et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol. 2005;21(3):154–60.
pubmed: 16335907
doi: 10.1080/09513590500231627
Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.
doi: 10.1016/j.fertnstert.2003.10.004
Aroda VR, Ciaraldi TP, Burke P, et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2009;94(2):469–76.
pubmed: 18984667
doi: 10.1210/jc.2008-1133
Cataldo NA, Abbasi F, McLaughlin TL, et al. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Hum Reprod. 2006;21(1):109–20.
pubmed: 16155076
doi: 10.1093/humrep/dei289
Jensterle M, Janez A, Mlinar B, Marc J, Prezelj J, Pfeifer M. Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur J Endocrinol. 2008;158(6):793–801.
pubmed: 18322300
doi: 10.1530/EJE-07-0857
Jensterle M, Sebestjen M, Janez A, et al. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol. 2008;159(4):399–406.
pubmed: 18653546
doi: 10.1530/EJE-08-0507
Steiner CA, Janez A, Jensterle M, Reisinger K, Forst T, Pfützner A. Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome. J Diabetes Sci Technol. 2007;1(2):211–7.
pubmed: 19888409
pmcid: 2771474
doi: 10.1177/193229680700100212
Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr J. 2005;52(3):299–308.
pubmed: 16006724
doi: 10.1507/endocrj.52.299
Anaforoglu I, Algun E, Incecayir O, Ersoy K. Higher metabolic risk with National Institutes of Health versus Rotterdam diagnostic criteria for polycystic ovarian syndrome in Turkish women. Metab Syndr Relat Disord. 2011;9(5):375–80.
pubmed: 21657888
doi: 10.1089/met.2011.0019
Du Q, Wang YJ, Yang S, Wu B, Han P, Zhao YY. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin. 2012;28(5):723–30.
pubmed: 22462531
doi: 10.1185/03007995.2012.681636
Xu Y, Wu Y, Huang Q. Comparison of the effect between pioglitazone and metformin in treating patients with PCOS: a meta-analysis. Arch Gynecol Obstet. 2017;296(4):661–77.
pubmed: 28770353
pmcid: 5591817
doi: 10.1007/s00404-017-4480-z
Huang R, Zhao PF, Xu JH, Liu DD, Luo FD, Dai YH. Effects of placebo-controlled insulin-sensitizing drugs on hormonal parameters in polycystic ovary syndrome patients: a network meta-analysis. J Cell Biochem. 2018;119(3):2501–11.
pubmed: 28941255
doi: 10.1002/jcb.26410
Zhao H, Xing C, Zhang J, He B. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021;18(1):171.
pubmed: 34407851
pmcid: 8371888
doi: 10.1186/s12978-021-01207-7
Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009;339: b2942.
pubmed: 19690342
pmcid: 2728804
doi: 10.1136/bmj.b2942
Froment P, Touraine P. Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS). PPAR Res. 2006;2006:73986.
pubmed: 17347533
pmcid: 1779579
doi: 10.1155/PPAR/2006/73986
Naka KK, Kalantaridou SN, Kravariti M, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril. 2011;95(1):203–9.
pubmed: 20684955
doi: 10.1016/j.fertnstert.2010.06.058
Ortega-González C, Luna S, Hernández L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(3):1360–5.
pubmed: 15598674
doi: 10.1210/jc.2004-1965
Batista JG, Soares JM, Maganhin CC, Simões RS, Tomaz G, Baracat EC. Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. Clinics (Sao Paulo). 2012;67(3):283–7.
pubmed: 22473412
doi: 10.6061/clinics/2012(03)14
Li T, Zhang T, Cui T, et al. Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome. J Steroid Biochem Mol Biol. 2020;204:105752.
pubmed: 32991990
doi: 10.1016/j.jsbmb.2020.105752
Glintborg D, Støving RK, Hagen C, et al. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(10):5605–12.
pubmed: 16076946
doi: 10.1210/jc.2005-0615
Glintborg D, Hermann AP, Andersen M, et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertil Steril. 2006;86(2):385–97.
pubmed: 16782094
doi: 10.1016/j.fertnstert.2005.12.067
Glintborg D, Frystyk J, Højlund K, et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol. 2008;68(2):165–74.
doi: 10.1111/j.1365-2265.2007.03015.x
Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod. 2006;21(6):1400–7.
pubmed: 16501039
doi: 10.1093/humrep/dei505